Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cyclacel Pharmaceuticals Inc

CYCC
Current price
0.29 USD +0.012 USD (+4.38%)
Last closed 0.27 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 412 291 USD
Yield for 12 month -61.91 %
Week
Month
Year
CYCC
21.11.2021 - 28.11.2021

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. Address: 200 Connell Drive, Berkeley Heights, NJ, United States, 07922

Analytics

WallStreet Target Price

13.67 USD

P/E ratio

Dividend Yield

2.82 %

Current Year

Last Year

Current Quarter

+16 000 USD

Last Quarter

+373 000 USD

Current Year

Last Year

Current Quarter

+16 000 USD

Last Quarter

+373 USD

Key Figures CYCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -28 907 000 USD
Operating Margin TTM -42781.25 %
PE Ratio
Return On Assets TTM -83.12 %
PEG Ratio
Return On Equity TTM -187.4 %
Wall Street Target Price 13.67 USD
Revenue TTM 389 000 USD
Book Value 0.34 USD
Revenue Per Share TTM 0.031 USD
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield 2.82 %
Gross Profit TTM -455 000 USD
Earnings Share -1.99 USD
Diluted Eps TTM -1.99 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CYCC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CYCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 2.82 %
Last Split Factor 1:20
Payout Ratio
Last Split Date 15.04.2020
Dividend Date 15.04.2020

Stock Valuation CYCC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 6.0999
Price Sales TTM 8.772
Enterprise Value EBITDA 0.0797
Price Book MRQ 0.8353

Financials CYCC

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CYCC

For 52 weeks

0.25 USD 1.17 USD
50 Day MA 0.45 USD
Shares Short Prior Month 512 309
200 Day MA 0.56 USD
Short Ratio 3.11
Shares Short 518 195
Short Percent 4.32 %